Vanda Pharmaceuticals
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Vanda Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#311 of 15,742 sponsors by registered trial count).
Vanda Pharmaceuticals: 68 sponsored US clinical trials, 15 recruiting.
Vanda Pharmaceuticals sponsors 68 registered US clinical trials on ClinicalTrials.gov, 15 of them currently recruiting, and 45 completed. 27 of these trials are in Phase 3-4 (later-stage) and 37 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Schizophrenia, with 5 trials.
Top-decile sponsor footprint
Vanda Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#311 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
45 of 49 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
68 total, page 1 of 2
A Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
NCT07446439
Open Label Study to Investigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chronic Plaque Psoriasis
NCT07362017
An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
NCT07179055
Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder
NCT07221578
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
NCT07090161
Randomized Withdrawal Study in Patients With Schizophrenia
NCT06961968
Evaluating the Effects of Tasimelteon vs. Placebo in Treating Pediatric Insomnia
NCT06953869
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
NCT06830044
A Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye
NCT06296966
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
NCT05648591
Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances
NCT05361707
Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD)
NCT04652882
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
NCT03838926
Development of Clinical Database of Individuals With Smith-Magenis Syndrome and Sleep Disturbances
NCT03154697
Patient Registry of Blind Subjects With Sleep-related Problems
NCT01195558
Treatment of Charcot-Marie-Tooth Disease, Axonal, Type 2S (CMT2S) in an Individual Patient
NCT07223632
Safety, Tolerability and Efficacy of Trichostatin A in Patients With Mild to Severe Onychomycosis
NCT07065773
Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness
NCT06138613
Study to Evaluate the Efficacy and Safety of Ponesimod (VSP-128) in Patients With Moderately to Severely Active Ulcerative Colitis
NCT07686081
A Study to Measure the Effects of Using Tradipitant on Nausea and Vomiting After GLP-1R Agonist Use
NCT06804603
Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions
NCT06494397
Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness
NCT05903924
Food Effect Study of VHX-896 in Healthy Volunteers
NCT06803290
Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy Volunteers
NCT05572281
Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
NCT05366855
Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
NCT05352893
Motion Syros: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
NCT04327661
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Hidradenitis Suppurativa
NCT04856930
Bioequivalence Study Between VHX-896 Tablets and Iloperidone Tablets in Healthy Volunteers
NCT04969211
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Acne Vulgaris
NCT04856917
A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform Rash
NCT04697069
Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder
NCT04819776
Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety
NCT04800237
Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers
NCT04849559
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis
NCT04697056
A Study to Evaluate Iloperidone Long-acting Injection (LAI) for the Treatment of Schizophrenia
NCT04712734
Safety and Efficacy of VSJ-110 in the Treatment of Allergic Conjunctivitis in Adults With a History of Ocular Allergies
NCT04622345
WGS Analysis of COVID-19 Positive Patients
NCT04353401
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)
NCT04140695
Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or Schizophrenia
NCT04127058
Evaluating the Safety and Efficacy of Tradipitant vs. Placebo in Idiopathic and Diabetic Gastroparesis
NCT04028492
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis
NCT03633396
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis
NCT03619902
Motion Sifnos: A Study to Investigate the Efficacy of Tradipitant in Subjects Affected by Motion Sickness
NCT03772340
Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE)
NCT03568331
Evaluating the Effects of Tasimelteon vs. Placebo on Jet Lag Type Insomnia
NCT03373201
Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis
NCT02970968
Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents
NCT02776215
A Proof of Concept Study to Evaluate the Effects of Tasimelteon and Placebo in Travelers With Jet Lag Disorder
NCT03291041
Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis
NCT02651714
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 17 |
| Phase 2 | 20 |
| Phase 3 | 26 |
| Phase 4 | 1 |
What is open in the Vanda Pharmaceuticals pipeline
15 recruiting of 68 indexed (22% open); 45 completed (66%).
Phase mix: 27 late (III/IV) vs 37 early (I/II) (balanced across stages).
Top condition: Schizophrenia (5 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Vanda Pharmaceuticals: open-pipeline peers nationwide
Peers matched on 68 registered trials and 22% open enrollment, not the therapeutic-area sidebar.
Vanda Pharmaceuticals sits below the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 68 trials (± recruiting share)
- Mallinckrodt · 69 trials · 0% recruiting
- Providence Health & Services · 69 trials · 7% recruiting
- Texas Tech University · 69 trials · 17% recruiting
- University of Colorado, Boulder · 69 trials · 22% recruiting
Sponsors near 22% open enrollment (± trial volume)
- Boston University Charles River Campus · 22% recruiting · 104 trials
- St. Jude Children's Research Hospital · 22% recruiting · 410 trials
- ALX Oncology · 22% recruiting · 9 trials
- Biosense Webster · 22% recruiting · 18 trials
Related
What to do with this Vanda Pharmaceuticals page
68 registered trials is a research-attention snapshot, not an endorsement of Vanda Pharmaceuticals or any single study.
- 15 of Vanda Pharmaceuticals's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Schizophrenia is the condition Vanda Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Schizophrenia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Vanda Pharmaceuticals pipeline card: 68 registered trials from official public datasets.Report a data error.